Try our beta test site
45 studies found for:    (lymphoma [CONDITION] [CONDITION]) AND PCI-32765 [TREATMENT] | Open Studies | NOT CLL
Show Display Options
Rank Status Study
1 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
2 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
3 Recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
4 Recruiting Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: bortezomib
5 Recruiting Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Conditions: Refractory Follicular Lymphoma;   Relapsed Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
6 Recruiting Evaluation of the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Condition: Mantle Cell Lymphoma
Interventions: Drug: IBRUTINIB;   Drug: Rituximab
7 Recruiting Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Conditions: T-cell Lymphoma;   Relapsed and Refractory T-cell Lymphoma
Intervention: Drug: Ibrutinib
8 Recruiting Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
Condition: Central Nervous System Lymphoma
Intervention: Drug: Imbruvica
9 Recruiting A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib + GA101 +GDC-0199
10 Recruiting RICE-ibrutinib in Relapsed DLBCL
Conditions: Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
Intervention: Drug: Ibrutinib-RICE
11 Recruiting Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
Condition: Indolent Non-Hodgkin Lymphoma
Interventions: Drug: Ibrutinib;   Drug: GA 101
12 Recruiting Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Conditions: Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab
13 Recruiting Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Lymphoma;   Follicular Lymphoma (FL)
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib
14 Recruiting Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab
15 Recruiting Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Condition: Treatment Naive Follicular Lymphoma
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
16 Recruiting Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Condition: Recurrent Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
17 Recruiting Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
Conditions: Follicular Lymphoma;   Follicular Lymphoma, Grade 1;   Follicular Lymphoma, Grade 2;   Follicular Lymphoma Grade IIIa
Intervention: Drug: Ibrutinib
18 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
19 Recruiting Evaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to Autologous Stem Cell Transplantation (ASCT)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatine;   Drug: Dexamethasone
20 Recruiting TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: PI3K-delta Inhibitor TGR-1202

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.